Actinogen Medical - Continued focus on Xanamem
Actinogen’s Q323 update reiterated the company’s focus on advancing its lead asset Xanamem. Patient recruitment in the Phase IIa XanaCIDD study in...
300 Views
Actinogen Medical - Getting ready for the next Alzheimer’s study
Actinogen is on track to start US recruitment in Q2 CY23 for the six-month, placebo-controlled Phase IIb portion of the XanaMIA study. The study...
344 Views
Actinogen Medical - On track to start Phase IIb XanaMIA study
Actinogen’s recent quarterly update confirmed that the company remains on track to start US recruitment in H1 CY23 for its six-month,...
385 Views
Actinogen Medical - XanaMIA clears hurdle to start US recruitment
Actinogen has announced that the US FDA has provided the required approvals for it to proceed with US recruitment for its planned six-month,...
808 Views
Actinogen Medical - XanaCIDD study in MDD now underway
Actinogen announced that the first patient was randomised and treated in its XanaCIDD Phase II study in major depressive disorder (MDD) assessing...
805 Views